Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
339.11
+1.05 (0.31%)
Feb 2, 2026, 4:00 PM EST - Market closed
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,230 employees as of December 31, 2024. The number of employees increased by 130 or 6.19% compared to the previous year.
Employees
2,230
Change (1Y)
130
Growth (1Y)
6.19%
Revenue / Employee
$1,439,493
Profits / Employee
$19,536
Market Cap
44.80B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 2,230 | 130 | 6.19% |
| Dec 31, 2023 | 2,100 | 98 | 4.90% |
| Dec 31, 2022 | 2,002 | 337 | 20.24% |
| Dec 31, 2021 | 1,665 | 212 | 14.59% |
| Dec 31, 2020 | 1,453 | 130 | 9.83% |
| Dec 31, 2019 | 1,323 | 258 | 24.23% |
| Dec 31, 2018 | 1,065 | 316 | 42.19% |
| Dec 31, 2017 | 749 | 235 | 45.72% |
| Dec 31, 2016 | 514 | 145 | 39.30% |
| Dec 31, 2015 | 369 | 113 | 44.14% |
| Dec 31, 2014 | 256 | 91 | 55.15% |
| Dec 31, 2013 | 165 | 36 | 27.91% |
| Dec 31, 2012 | 129 | 13 | 11.21% |
| Dec 31, 2011 | 116 | -56 | -32.56% |
| Dec 31, 2010 | 172 | -6 | -3.37% |
| Dec 31, 2009 | 178 | 8 | 4.71% |
| Dec 31, 2008 | 170 | 41 | 31.78% |
| Dec 31, 2007 | 129 | 7 | 5.74% |
| Dec 31, 2006 | 122 | 28 | 29.79% |
| Dec 31, 2005 | 94 | 23 | 32.39% |
| Dec 31, 2004 | 71 | 11 | 18.33% |
| Dec 31, 2003 | 60 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,106 |
| BeOne Medicines AG | 11,000 |
| BioNTech SE | 6,772 |
| Vertex Pharmaceuticals | 6,100 |
| Moderna | 5,800 |
| Genmab | 2,681 |
| Incyte | 2,617 |
| argenx SE | 1,599 |
ALNY News
- 5 days ago - Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 21 days ago - Alnylam Pharmaceuticals, Inc. (ALNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 21 days ago - Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale - Benzinga
- 22 days ago - Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact - Business Wire
- 4 weeks ago - Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 6 weeks ago - Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics - Business Wire
- 7 weeks ago - Is Alnylam Entering A Corrective Phase After A Strong Run? - Benzinga
- 7 weeks ago - Walmart was too late for a Nasdaq-100 spot — but these 6 stocks made the cut - Market Watch